CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents.

Behavioural Pharmacology
J HallerT F Freund

Abstract

Cannabinoids are known to modulate GABAergic and glutamatergic transmission in cortical areas, the former via CB1 and the latter via a novel receptor. Pharmacological data demonstrate that several widely used cannabinoid ligands bind to both receptors, which may explain the inconsistencies in their behavioural effects. Earlier we showed that the cannabinoid antagonist SR-141716A affected behaviour in both CB1 knockout and wild-type animals, and its effect (anxiolysis) was different from that of CB1 gene disruption (anxiogenesis). In the present experiments, we studied the effects of the CB1 antagonist AM-251, and the cannabinoid agonist WIN-55,212-2 in wild-type as well as in CB1 knockout mice. CB1 knockout mice showed higher scores of anxiety-like behaviour than the wild-type animals in the elevated plus-maze. Selective blockade of CB1 receptors by AM-251 (0.3, 1 and 3 mg/kg) increased anxiety-like behaviour dose-dependently in the wild-type mice but had no effect in the knockouts. In wild types, the cannabinoid agonist WIN-55,212-2 (1 and 3 mg/kg) caused a decrease in anxiety-like behaviour, which was abolished by the CB1-selective antagonist AM-251 (3 mg/kg). The same agonist did not change plus-maze behaviour in CB1 knockou...Continue Reading

References

Jul 1, 1991·Neuropeptides·B CostallG N Woodruff
Jan 1, 1990·Pharmacology & Therapeutics·B CostallM B Tyers
Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M HerkenhamK C Rice
Dec 14, 1995·Behavioural Brain Research·E S OnaiviG Chaudhuri
May 5, 1998·Neurochemical Research·F E Bloom, M Morales
Dec 3, 1998·Experimental Brain Research·H FinkJ P Voigt
May 13, 1999·Proceedings of the National Academy of Sciences of the United States of America·A ZimmerT I Bonner
Sep 24, 1999·Neurochemical Research·B E AkinsholaE S Onaivi
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·Z JáraiG Kunos
Jun 6, 2000·Pharmacology, Biochemistry, and Behavior·S E FileS Cheeta
Dec 5, 2000·Behavioural Pharmacology·B Scatton, D J Sanger
Feb 2, 2002·Psychopharmacology·Miquel MartinOlga Valverde
Oct 31, 2002·The European Journal of Neuroscience·J HallerT F Freund
Dec 4, 2002·Nature Medicine·Satish KathuriaDaniele Piomelli
Jul 10, 2003·Lancet Neurology·David BakerAlan J Thompson
Aug 21, 2003·Progress in Neurobiology·Mark J Millan
Sep 2, 2003·Trends in Neurosciences·Tamás F Freund
Sep 18, 2003·The British Journal of Nutrition·Joanne A Harrold, Gareth Williams
Oct 8, 2003·Current Drug Targets. CNS and Neurological Disorders·I Lastres-BeckerJ J Fernández-Ruiz
Oct 8, 2003·Current Medicinal Chemistry·Alison J Drysdale, Bettina Platt
Oct 8, 2003·Mini Reviews in Medicinal Chemistry·P GoyaM I Martin
Nov 8, 2003·Trends in Molecular Medicine·Silvana GaetaniDaniele Piomelli
Dec 24, 2003·Drug Discovery Today·John F CryanAthina Markou

❮ Previous
Next ❯

Citations

Jun 12, 2008·Psychopharmacology·Anna M MoiseAndrea G Hohmann
Feb 27, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gabriella JuhaszJ F William Deakin
Jul 29, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wei WangQing-song Liu
Sep 23, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Plínio C CasarottoFabrício A Moreira
Mar 17, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Marco BortolatoDaniele Piomelli
Feb 2, 2011·Proceedings of the National Academy of Sciences of the United States of America·Takayuki YoshidaMasahiko Watanabe
Apr 28, 2011·Addiction Biology·Islam GamaleddinBernard Le Foll
Jan 26, 2007·Clinical and Experimental Pharmacology & Physiology·Ali RoohbakhshMohammad-Reza Zarrindast
Jul 14, 2009·The Journal of Pharmacology and Experimental Therapeutics·Samir Haj-Dahmane, Roh-Yu Shen
Sep 14, 2006·Pharmacological Reviews·Pál PacherGeorge Kunos
Jul 20, 2011·Journal of Psychopharmacology·S RuehleB Lutz
Nov 30, 2013·Biology of Mood & Anxiety Disorders·Matthew N Hill, Sachin Patel
May 17, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Christine E WellsColin Lever
Sep 9, 2011·Future Neurology·Simone B SartoriNicolas Singewald
Oct 22, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Bernard Le FollJose M Trigo
Dec 15, 2005·Proceedings of the National Academy of Sciences of the United States of America·G GobbiD Piomelli
Dec 20, 2008·Neural Plasticity·F A MoreiraF S Guimarães
Jun 3, 2014·Pharmacology, Biochemistry, and Behavior·Larissa KochenborgerMoacir Serralvo Faria
Jun 2, 2012·Expert Opinion on Drug Discovery·Adam StewartAllan V Kalueff
Feb 26, 2016·Physiology & Behavior·Anne Q Fosnocht, Lisa A Briand
Jan 18, 2012·Neuropharmacology·Sudhir N UmatheNishant S Jain
Feb 3, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ana Franky Carvalho, Elisabeth J Van Bockstaele
Sep 20, 2011·Behavioural Brain Research·Kertu RünkorgEero Vasar
Aug 11, 2011·Neuroscience·R J McLaughlin, G Gobbi
Apr 1, 2010·Experimental Neurology·Daniela ParolaroTiziana Rubino
Dec 18, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·K S SinkJ D Salamone
Oct 27, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Aet AlttoaJaanus Harro
May 23, 2009·Behavioural Brain Research·Christian G ReichMargaret M McCarthy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.